As detailed below, a potential return-on-investment result is +0.9% absolute return (equivalent to +39.8% annualized return for the next 8 days) if the stock is assigned early (last trading day prior to July 3rd ex-date); OR +1.8% absolute return (equivalent to +27.5% annualized return over the next 24 days) if the stock is assigned on the July 19th options expiration date.
Bristol-Myers Squibb Co. (BMY) -- New Covered Calls Position
Although unlikely, if the current time value (i.e. extrinsic value) of $.39 = [$1.47 options premium - ($45.08 stock price - $44.00 strike price)] remaining in the three short Call options decays substantially (down to about $.10 or less) by July 2nd (the last trading day prior to the ex-dividend date), there is a possibility that the Call options owner would exercise early and therefore call the 300 Bristol-Myers shares away to capture the dividend payment.
The buy/write transaction was:
06/26/2019 Bought 300 Bristol-Myers shares @ $45.08
06/26/2019 Sold 3 BMY 7/19/2019 $44.00 Call options @ $1.47
Note: the Open Interest in these Call options was 223 contracts and the Implied Volatility was 23.8 when this transaction was executed.
07/03/2019 Upcoming quarterly ex-dividend of $.41 per share
Two possible overall performance results (including commissions) for this Bristol-Myers Covered Calls position are as follows:
Covered Calls Cost Basis: $13,087.95
= ($45.08 - $1.47) * 300 shares + $4.95 commissions
Net Profit Components:
(a) Options Income: +$443.01
= ($1.47 *300 shares) + $2.01 commission
(b) Dividend Income (If option exercised early on July 2nd, the business day prior to July 3rd ex-div date): +$0.00; or
(b) Dividend Income (If Bristol-Myers shares assigned at July 19th, 2019 expiration): +$123.00
= ($.41 dividend per share x 300 shares)
(c) Capital Appreciation (If BMY assigned early on July 2nd): -$328.95
+($44.00 -$45.08)*300 shares - $4.95 commissions; or
(c) Capital Appreciation (If BMY assigned at $44.00 strike price at options expiration): -$328.95
+($44.00 -$45.08)*300 shares - $4.95 commissions
+($44.00 -$45.08)*300 shares - $4.95 commissions; or
(c) Capital Appreciation (If BMY assigned at $44.00 strike price at options expiration): -$328.95
+($44.00 -$45.08)*300 shares - $4.95 commissions
1. Total Net Profit [If option exercised on Apr 3rd (business day prior to Apr 4th ex-dividend date)]: +$114.06
= (+$443.01 options income +$0.00 dividend income -$328.95 capital appreciation); or
2. Total Net Profit (If Bristol-Myers shares assigned at $44.00 at July 19, 2019 expiration): +$237.06
= (+$443.01 options income +$123.00 dividend income -$328.95 capital appreciation)
1. Absolute Return (If BMY option exercised early): +0.9%
= +$114.06/$13,087.95
Annualized Return: +39.8%
= (+$114.06/$13,087.95)*(365/8 days); or
2. Absolute Return (If Bristol-Myers shares assigned at $44.00 at July 19th, 2019 expiration): +1.8%
= +$237.06/$13,087.95
Annualized Return: +27.5%
= (+$237.06/$13,087.95)*(365/24 days)
Either outcome would provide an excellent return-on-investment result. These returns will be achieved as long as the stock is above the $44.00 strike price at assignment. If the stock declines below the strike price, the breakeven price of $43.20 ($45.08 -$1.47 -$.41) provides 4.2% downside protection below today's purchase price.
The Covered Calls Advisor has established a set of eleven criteria to evaluate potential Covered Calls using a dividend capture strategy. The minimum threshold desired to establish a position is that at least nine of these eleven criteria must be achieved. As shown in the table below, all of the eleven criteria are achieved for this Bristol-Myers Covered Calls position.